Figure 1: Co-localization of HDAC6 with p150 glued and the microtubule network. Figure 4: Overexpression of HDAC6 increases the chemotactic motility of NIH-3T3 cells. Flag-tagged pBJ5-HDAC6 expression ...

Histone deacetylases (HDACs) are important epigenetic regulators, which impact chromatin condensation and gene expression. HDAC6 is a member of the Class IIB HDAC family, and appears to be important ...

BOSTON—In people with Alzheimer’s disease (AD), the epigenetic regulator HDAC6 (histone deacetylase 6), which controls many biological processes, is significantly overexpressed in the brain. Evidence ...

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver ...

Heart disease is the leading cause of death globally. Therefore, developing novel ways to treat the rare and/or common forms of the disease is critical. Now, Tenaya Therapeutics, a company focused on ...

Increased health and survival of motor neurons and reduced plasma neurofilament light chain (NfL) observed, underscoring disease-modifying potential of CNS-penetrant HDAC6 inhibitors, including ...

Eikonizo Therapeutics Inc. has described histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of cancer, multiple sclerosis, systemic lupus erythematosus, neurodegeneration ...

Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in the western world and is characterized by an accumulation of CD5+ B cells in circulation and lymphoid tissue. There is a need to ...

Mark A. Rivieccio, Camille Brochier, Dianna E. Willis, Breset A. Walker, Melissa A. D'Annibale, Kathryn McLaughlin, Ambreena Siddiq, Alan P. Kozikowski, Samie R. Jaffrey, Jeffery L. Twiss, Rajiv R.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the ...